Goserelin extended release - Luye Pharma Group

Drug Profile

Goserelin extended release - Luye Pharma Group

Alternative Names: Goserelin acetate extended release - Luye Pharma Group; LY 01005

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Luye Pharma Group
  • Class Antineoplastics; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Prostate cancer

Most Recent Events

  • 31 Aug 2016 Luye Pharma plans a phase I trial for Breast cancer and Prostate cancer in USA and China
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top